Compare · LUNG vs MDLN
LUNG vs MDLN
Side-by-side comparison of Pulmonx Corporation (LUNG) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUNG and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 605.1x LUNG ($79.5M).
- MDLN has been more active in the news (7 items in the past 4 weeks vs 1 for LUNG).
- MDLN has more recent analyst coverage (25 ratings vs 17 for LUNG).
- Company
- Pulmonx Corporation
- Medline Inc.
- Price
- -
- -
- Market cap
- $79.5M
- $48.08B
- 1M return
- -
- +11.97%
- 1Y return
- -
- -11.77%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2025
- News (4w)
- 1
- 7
- Recent ratings
- 17
- 25
Pulmonx Corporation
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Latest LUNG
- Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026
- SEC Form 4 filed by Pulmonx Corporation
- Chief Science & Techn. Officer Radhakrishnan Srikanth sold $32,194 worth of shares (14,245 units at $2.26), decreasing direct ownership by 4% to 316,994 units (SEC Form 4) (tax withholding)
- General Counsel Lehman David Aaron sold $32,395 worth of shares (14,334 units at $2.26), decreasing direct ownership by 4% to 361,827 units (SEC Form 4) (tax liability)
- Chief Commercial Officer Rose Geoffrey Beran sold $17,807 worth of shares (7,879 units at $2.26), decreasing direct ownership by 2% to 449,832 units (SEC Form 4) (tax withholding)
- Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pulmonx to Participate in Upcoming Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Pulmonx Corporation
- SEC Form 10-Q filed by Pulmonx Corporation
- Pulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M